IOLCP.NS Stock Analysis
IO
Avoid
Based on Eyestock quantitative analysis, IOLCP.NS`s fundamental data and valuation indicate an investment grade of Avoid at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Moderate score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Greatly overvalued
IOL Chemicals & Pharmaceuticals Ltd. engages in the manufacture of organic and inorganic chemical compounds. The company is headquartered in Ludhiana, Punjab and currently employs 2,557 full-time employees. The company went IPO on 2010-11-05. The firm's APIs portfolio covers various therapeutic categories, such as pain management, anti-diabetic, anti-hypertensive, and anti-convulsant, amongst others. The firm operates through two business divisions: Active Pharma Ingredients (API), and Specialty Chemicals. Its API vertical is engaged in research, developing, and providing various essential products that are used by pharma companies. Its API product portfolio includes Ibuprofen, Ibuprofen Lysinate, Ibuprofen Sodium, Dex-Ibuprofen, Metformin HCL, Clopidogrel Bisulphate (Form II), Pantoprazole Sodium, Fenofibrate, Gabapentin, Lamotrigine, Ursodeoxycholic Acid, Losartan Potassium and Levetiracetam. Its Specialty Chemical division includes Ethyl Acetate, Iso Butyl Benzene, Acetyl Chloride and Mono Chloro Acetic Acid.